722 Stock Overview A biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Antengene Corporation Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Antengene Historical stock prices Current Share Price HK$0.057 52 Week High HK$0.21 52 Week Low HK$0.025 Beta 0.73 1 Month Change 14.00% 3 Month Change 48.05% 1 Year Change -67.05% 3 Year Change -94.52% 5 Year Change n/a Change since IPO -96.80%
Recent News & Updates
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Aug 27
Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024 Aug 01 See more updates
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
First half 2024 earnings released: CN¥0.27 loss per share (vs CN¥0.36 loss in 1H 2023) Aug 27
Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024 Aug 01
Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024 Jul 31
Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country Jul 06
Full year 2023 earnings released: CN¥0.94 loss per share (vs CN¥0.97 loss in FY 2022) Mar 24
Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024 Mar 23
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study Mar 20
Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024 Mar 12
New minor risk - Market cap size Mar 04
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Dec 14
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States Dec 11
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Dec 06
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day Nov 17
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 Sep 22
New minor risk - Shareholder dilution Sep 20
First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022) Aug 27
Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 16
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jul 17
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jun 03
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers May 24
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 May 18
Less than half of directors are independent Mar 27
Antengene Corporation Limited Announces Executive Changes Dec 07
Less than half of directors are independent Nov 16
Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer Nov 16
Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting Nov 08
Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037 Nov 03
Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors Nov 01
Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma Oct 22
First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021) Sep 02
Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma Aug 03 Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022
Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors Jun 08
Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018 Jun 07
Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors May 31
Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas May 23
Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China May 19
Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 18
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 16
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress May 14
Less than half of directors are independent Apr 27
Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018 Apr 27
Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine Apr 07
Antengene Corporation Limited Announces Management Changes Mar 31
Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes Mar 30 Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 Feb 07
Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors Dec 30
Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial Dec 20
National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China Dec 18
Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting Dec 15
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors Dec 13
Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China Aug 24
Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma Jul 23
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF) Jul 07 Shareholder Returns 722 DE Pharmaceuticals DE Market 7D 26.7% -2.2% -2.0% 1Y -67.1% -15.6% 6.9%
See full shareholder returns
Return vs Market: 722 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 722's price volatile compared to industry and market? 722 volatility 722 Average Weekly Movement 29.4% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 722's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 722's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors.
Show more Antengene Corporation Limited Fundamentals Summary How do Antengene's earnings and revenue compare to its market cap? 722 fundamental statistics Market cap €52.76m Earnings (TTM ) -€69.56m Revenue (TTM ) €7.36m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 722 income statement (TTM ) Revenue CN¥56.07m Cost of Revenue CN¥8.50m Gross Profit CN¥47.57m Other Expenses CN¥577.09m Earnings -CN¥529.52m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.78 Gross Margin 84.84% Net Profit Margin -944.43% Debt/Equity Ratio 18.1%
How did 722 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 10:42 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Antengene Corporation Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ziyu He China International Capital Corporation Limited Wangbin Zhou Citigroup Inc Ruili Bian Citigroup Inc
Show 4 more analysts 